Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Cancer Research UK Phase I Trial of the Anti-CD19 DI-B4 Monoclonal Antibody Given Intravenously, Weekly for Four Weeks, in Patients With Advanced CD19 Positive Indolent B-cell Malignancies

NCT01805375 is registered in ClinicalTrials.gov with Cancer Research UK as lead sponsor.

NCT NCT01805375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01805375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Cancer Research UK Phase I Trial of the Anti-CD19 DI-B4 Monoclonal Antibody Given Intravenously, Weekly for Four Weeks, in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
Lead sponsor
Cancer Research UK
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2013
Completion date
December 14, 2017
Enrollment
28 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukaemia, indolent b-cell lymphoma, waldenström macroglobulinaemia